Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study.
Saved in:
| Title: | Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study. |
|---|---|
| Authors: | Chen, Likun1 (AUTHOR), Rangel, Jose David Gomez2 (AUTHOR), Cil, Timucin3 (AUTHOR), Li, Xingya4 (AUTHOR), Cicin, Irfan5 (AUTHOR), Shen, Yihong6 (AUTHOR), Liu, Zhihua7 (AUTHOR), Ozyilkan, Ozgur8 (AUTHOR), Igor, Bondarenko9 (AUTHOR), Chen, Jun10 (AUTHOR), Oleksandr, Kostiuk11 (AUTHOR), Chen, Zhendong12 (AUTHOR), Zhang, Helong13 (AUTHOR), Fu, Ziyi14 (AUTHOR), Dong, Qingfeng14 (AUTHOR), Song, Shuqiang14 (AUTHOR), Yu, Jin‐Chen14 (AUTHOR), Zhang, Li1 (AUTHOR) zhangli@sysucc.org.cn, Hryhoriy, Adamchuk (AUTHOR), Karaoglu, Aziz (AUTHOR) |
| Source: | Cancer Medicine. Nov2023, Vol. 12 Issue 22, p20847-20863. 17p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20457634 |
|---|---|
| DOI: | 10.1002/cam4.6664 |
